Free Trial
NASDAQ:RNAC

Cartesian Therapeutics (RNAC) Stock Price, News & Analysis

Cartesian Therapeutics logo
$13.54 -0.23 (-1.67%)
Closing price 04:00 PM Eastern
Extended Trading
$13.58 +0.04 (+0.30%)
As of 04:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Cartesian Therapeutics Stock (NASDAQ:RNAC)

Key Stats

Today's Range
$13.33
$14.37
50-Day Range
$8.77
$13.77
52-Week Range
$8.46
$26.50
Volume
96,371 shs
Average Volume
99,902 shs
Market Capitalization
$351.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$40.00
Consensus Rating
Moderate Buy

Company Overview

Cartesian Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
45th Percentile Overall Score

RNAC MarketRank™: 

Cartesian Therapeutics scored higher than 45% of companies evaluated by MarketBeat, and ranked 615th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cartesian Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Cartesian Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Cartesian Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Cartesian Therapeutics are expected to decrease in the coming year, from $4.56 to ($3.07) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cartesian Therapeutics is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cartesian Therapeutics is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Cartesian Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    31.65% of the float of Cartesian Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Cartesian Therapeutics has a short interest ratio ("days to cover") of 31, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Cartesian Therapeutics has recently increased by 3.14%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Cartesian Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Cartesian Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    31.65% of the float of Cartesian Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Cartesian Therapeutics has a short interest ratio ("days to cover") of 31, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Cartesian Therapeutics has recently increased by 3.14%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Cartesian Therapeutics has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Cartesian Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    2 people have searched for RNAC on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cartesian Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    60.30% of the stock of Cartesian Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    86.95% of the stock of Cartesian Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Cartesian Therapeutics' insider trading history.
Receive RNAC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cartesian Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RNAC Stock News Headlines

This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
See More Headlines

RNAC Stock Analysis - Frequently Asked Questions

Cartesian Therapeutics' stock was trading at $17.91 at the start of the year. Since then, RNAC stock has decreased by 24.0% and is now trading at $13.62.

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) issued its earnings results on Thursday, May, 8th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.61) by $0.07. The firm earned $1.10 million during the quarter, compared to analyst estimates of $0.69 million.

Cartesian Therapeutics shares reverse split on Friday, April 5th 2024.The 1-30 reverse split was announced on Friday, April 5th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Shares of RNAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cartesian Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG).

Company Calendar

Last Earnings
5/08/2025
Today
7/10/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RNAC
Previous Symbol
NASDAQ:RNAC
CIK
1453687
Employees
64
Year Founded
N/A

Price Target and Rating

High Price Target
$42.00
Low Price Target
$38.00
Potential Upside/Downside
+192.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($52.83)
Trailing P/E Ratio
N/A
Forward P/E Ratio
3.00
P/E Growth
N/A
Net Income
-$77.42 million
Net Margins
N/A
Pretax Margin
-111.27%
Return on Equity
N/A
Return on Assets
-7.01%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
12.34
Quick Ratio
12.34

Sales & Book Value

Annual Sales
$38.91 million
Price / Sales
9.12
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.27) per share
Price / Book
-50.67

Miscellaneous

Outstanding Shares
25,950,000
Free Float
10,304,000
Market Cap
$355.00 million
Optionable
Optionable
Beta
0.36
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:RNAC) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners